SCHEMBL4767769

SCHEMBL4767769

COC(=O)c1ccc(NS(=O)(=O)CCc2cccc(Cl)c2Cl)c(C)c1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.45
LMNA P02545 1/20 0.45
ALDH1A1 P00352 5/20 0.44
KDM4E B2RXH2 2/20 0.44
HPGD P15428 1/20 0.44
PTGES2 Q9H7Z7 6/20 0.41
KMT2A Q03164 1/20 0.41
PFKFB3 Q16875 1/20 0.39
PFKFB4 Q16877 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
TSHR P16473 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
POLB P06746 1/20 0.38
TP53 P04637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HSD17B10 Q99714 1/20 0.38
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4767669 0.91 MAPT (0.46) MAPTLMNAALDH1A1KDM4EHPGD
SCHEMBL4771005 0.83 POLB (0.55) MAPTLMNAALDH1A1HPGDKMT2A
SCHEMBL4777535 0.81 PTGES2 (0.49) MAPTLMNAALDH1A1KDM4EHPGD
SCHEMBL1478533 0.78 ALDH1A1 (0.50) MAPTLMNAALDH1A1KDM4EHPGD
SCHEMBL4771118 0.78 SMN1; SMN2 (0.46) MAPTLMNAALDH1A1HPGDKMT2A
SCHEMBL1479464 0.76 ALDH1A1 (0.48) MAPTLMNAALDH1A1KDM4EHPGD
SCHEMBL4774741 0.75 HPGD (0.58) MAPTLMNAALDH1A1HPGDPTGES2
SCHEMBL4776450 0.74 STAT3 (0.44) MAPTLMNAHPGDPTGES2SMN1; SMN2
SCHEMBL4774787 0.72 HPGD (0.47) MAPTALDH1A1HPGDKMT2AHTT
SCHEMBL4773377 0.72 EDNRA (0.39) MAPTLMNAALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 MAPT 294/4885LMNA 1022/4885ALDH1A1 2159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.